Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach

Experimental Hematology
Elliot M EpnerThomas P Loughran

Abstract

We recently reported that addition of epigenetic agents could overcome resistance of leukemic cells to monoclonal antibody-mediated anti-tumor effects in T-cell prolymphocytic leukemia. We also reported that epigenetic agents could induce expression of the CD30 gene, thus providing a therapeutic target for the antibody drug conjugate brentuximab vedotin. Here we discuss these findings and their generality to treatment of other hematologic and solid malignancies.

References

Mar 12, 2009·Expert Review of Anticancer Therapy·Amit Khot, Claire Dearden
May 6, 2009·Leukemia Research·Enrico OrciuoloMario Petrini
Oct 15, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G CervettiM Petrini
Mar 31, 2010·Seminars in Hematology·Ronald P Taylor, Margaret A Lindorfer
Jun 29, 2011·Anti-cancer Agents in Medicinal Chemistry·Brian M BarthMark Kester
Jun 1, 2012·Blood·Claire Dearden
Jul 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Franck Andre MorschhauserGilles Andre Salles
Apr 4, 2015·Biological Chemistry·Mark KesterMylisa R Parette
Jun 26, 2015·Science Translational Medicine·Zainul S HasanaliElliot M Epner

❮ Previous
Next ❯

Citations

Jan 18, 2017·Cold Spring Harbor Perspectives in Medicine·David G Kent, Anthony R Green
Dec 22, 2017·Oncotarget·Kamel LaribiAlix Baugier de Materre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex, associated with a generally dismal prognosis owing to its aggressive behavior. Here are the latest discoveries pertaining to this disease.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Related Papers

Nature Reviews. Drug Discovery
Anas YounesPeter Kirkpatrick
Biologics in Therapy
Guilherme Fleury Perini, Barbara Pro
Expert Opinion on Biological Therapy
Barbara Pro, Guilherme Fleury Perini
© 2022 Meta ULC. All rights reserved